MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4143/crt.2020.245

Медицинская библиотека · Cancer research and treatment · 2020

Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea.

Lim Sun Min, Kim Sang-We, Cho Byoung Chul, Kang Jin Hyung, Ahn Myung-Ju, Kim Dong-Wan, Kim Young-Chul, Lee Jin Soo, Lee Jong-Seok, Lee Sung Yong, Park Keon Uk, An Ho Jung, Cho Eun Kyung, Jang Tae Won, Kim Bong-Seog, Kim Joo-Hang, Lee Sung Sook, Na Im-Ii, Yoo Seung Soo, Lee Ki Hyeong

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

PURPOSE: The introduction of immune checkpoint inhibitors represents a major advance in the treatment of lung cancer, allowing sustained recovery in a significant proportion of patients. Nivolumab is a monoclonal anti-programmed death cell protein 1 antibody licensed for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. In this study, we describe the demographic and clinical outcomes of patients with advanced NSCLC treated with nivolumab in the Korean expanded access program.

MATERIALS AND

METHODS

Previously treated patients with advanced nonsquamous and squamous NSCLC patients received nivolumab at 3 mg/kg every 2 weeks up to 36 months. Efficacy data including investigator-assessed tumor response, progression data, survival, and safety data were collected.

RESULTS

Two hundred ninety-nine patients were treated across 36 Korean centers. The objective response rate and disease control rate were 18% and 49%, respectively; the median progression-free survival was 2.1 months (95% confidence interval [CI], 1.87 to 3.45), and the overall survival (OS) was 13.2 months (95% CI, 10.6 to 18.9). Patients with smoking history and patients who experienced immune-related adverse events showed a prolonged OS. Cox regression analysis identified smoking history, presence of immune-related adverse events as positive factors associated with OS, while liver metastasis was a negative factor associated with OS. The safety profile was generally comparable to previously reported data.

CONCLUSION

This real-world analysis supports the use of nivolumab for pretreated NSCLC patients, including those with an older age.

Для цитирования: Lim Sun Min, Kim Sang-We, Cho Byoung Chul, Kang Jin Hyung, Ahn Myung-Ju, Kim Dong-Wan, Kim Young-Chul, Lee Jin Soo, Lee Jong-Seok, Lee Sung Yong, Park Keon Uk, An Ho Jung, Cho Eun Kyung, Jang Tae Won, Kim Bong-Seog, Kim Joo-Hang, Lee Sung Sook, Na Im-Ii, Yoo Seung Soo, Lee Ki Hyeong. Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea.. Cancer research and treatment. 2020. DOI: 10.4143/crt.2020.245.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.